Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 4 April, 2025 – Reference is made to the inventory change discover printed by Zelluna ASA (the “Firm“) on 27 March 2025 relating to key info on the reverse share cut up at a ratio of 10:1.

Radforsk Investeringsstiftelse (“Radforsk“) has beforehand agreed with the Firm to make accessible, with none compensation a, obligatory quantity of shares to make sure that all fractions of shares are rounded as much as the closest entire share, thus avoiding that shareholders may have its shareholdings rounded off downwards.

Radforsk has right now transferred a complete of 1730 shares to DNB Financial institution ASA, registrar’s division, for deletion, to make sure that all fractions of shares are rounded as much as the closest entire share within the reverse share cut up.

The Firm has thus obtained the next notification of a transaction made by a close associate of a primary insider:

• Radforsk Investeringsstiftelse, a close associate of Anders Tuv, Chair of the board of administrators and primary insider of the Firm, has right now transferred 1730 current shares within the Firm to DNB Financial institution ASA, registrar’s division, at a value of NOK 1 per share (equal to the par worth).

The notification regarding the above subscription is connected hereto.

For additional info, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Electronic mail: hans.eid@zelluna.com
Cellphone: +47 482 48632

About Zelluna ASA
Zelluna’s mission is to ship transformative therapies with the capability to treatment superior stable cancers, in a protected and cost-efficient method, to sufferers on a worldwide scale. The Firm goals to do that by combining probably the most highly effective parts of the immune system by means of pioneering the event of “off the shelf” T cell receptor (TCR) guided pure killer (NK) cell therapies (TCR-NK). The TCR-NK platform presents a novel mechanism of motion with broad most cancers detection functionality to beat the variety of tumours and can be used “off the shelf” to beat scaling limitations of present cell therapies. The lead program is a world’s first MAGE-A4 focusing on “off the shelf” TCR-NK for the therapy of varied stable cancers; a pipeline of earlier merchandise follows. The Firm is led by a administration workforce of biotech entrepreneurs with deep expertise in discovery by means of to medical growth of TCR and cell-based therapies together with marketed merchandise.

• 20250404 – Zelluna ASA – PDMR attachment